Location History:
- Gaithersburg, MD (US) (1999 - 2000)
- Gaithersberg, MD (US) (2001)
- Alpharetta, GA (US) (2004 - 2024)
Company Filing History:
9 out of 987 
5 out of 19 
1 out of 4,945 
Years Active: 1999-2025
Title: **The Innovations of Abel De La Rosa**
Introduction
Abel De La Rosa, an accomplished inventor based in Alpharetta, GA, has made significant contributions to the field of medicine, particularly in the treatment of viral infections. With a portfolio of 14 patents, his innovations focus on the development of novel pharmaceutical compounds aimed at combating infectious diseases.
Latest Patents
Among his latest innovations is a patent for "Phosphoramidates for the treatment of hepatitis B virus." This inventive disclosure outlines compounds that can effectively treat infectious diseases, with specific derivatives of clevudine being highlighted. In addition, he holds a patent related to "Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections." This patent discusses therapeutic compositions that contain a compound of a specific formula, or a pharmaceutically acceptable salt thereof, emphasizing the treatment potential in viral infection scenarios.
Career Highlights
Abel has gained valuable experience working in renowned institutions, including Emory University and Digene Corporation. His tenure at these organizations has contributed to his expertise in the development of medical therapies, allowing him to innovate and implement solutions to pressing health issues.
Collaborations
Throughout his career, Abel has collaborated with notable professionals in the field, including Gregory R Bluemling and George R Painter. These partnerships have likely enriched his research output and expanded the horizons of his inventive contributions.
Conclusion
Abel De La Rosa exemplifies the spirit of innovation in medicine, particularly in his pursuit of effective treatments for viral infections. With a robust portfolio of patents and a proven track record in esteemed organizations, he remains a significant figure in the landscape of pharmaceutical invention. His work continues to pave the way for advancements that could have substantial impacts on public health.